7.64

6.03% -0.49

After Hours: 7.66 0.02 +0.26%

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $7.64, with a volume of 1.02M. It is down -6.03% in the last 24 hours and down -13.96% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$8.13

Open:

$8.15

24h Volume:

1.02M

Relative Volume:

1.17

Market Cap:

$1.20B

Revenue:

$61.10M

Net Income/Loss:

$-138.36M

P/E Ratio:

-5.6593

EPS:

-1.35

Net Cash Flow:

$-90.59M

1W Performance:

-1.80%

1M Performance:

-13.96%

6M Performance:

-3.17%

1Y Performance:

+51.59%

1-Day Range:

$7.63

$8.20

1-Week Range:

$7.45

$8.31

52-Week Range:

$4.06

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

267

Twitter

@OCUTX

Next Earnings Date

2024-11-05

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	7.64	1.20B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

Feb 06, 2025

Is Ocular Therapeutix Inc (OCUL) a good investment opportunity? - US Post News

Feb 06, 2025

Raymond James maintains $19 target on Ocular Therapeutix stock - MSN

Feb 06, 2025

Feb 05, 2025